Blood monocytes from mammary tumor-bearing mice: Early targets of tumor-induced immune suppression?

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 891-900

  Caso, Raul ^a   Silvera, Risset ^b   Carrio, Roberto ^b   Iragavarapu Charyulu, Viyaya ^c   Gonzalez Perez, Ruben R ^d   Torroella Kouri, Marta ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Immune suppression; Inflammation; Macrophages; Monocytes

Indexed keywords

ALPHA INTERFERON; ANGIOPOIETIN RECEPTOR; ARGINASE; CD11B ANTIGEN; CD68 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; COMPLEMENT COMPONENT C3; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12P35; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; L SELECTIN; NITRIC OXIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROARRAY ANALYSIS; MONOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, LY; ARGINASE; CELL DIFFERENTIATION; CELL SEPARATION; CELLS, CULTURED; CHEMOKINES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; L-SELECTIN; LEUKOCYTE COUNT; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MONOCYTES; NITRIC OXIDE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TUMOR ESCAPE;

EID: 77956524617     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000740     Document Type: Article

References (51)

1. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005. (Pubitemid 40568680)
2. Li H, Fan X and Houghton J: Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 101: 805-815, 2007.
3. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
4. Qian BZ and Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51, 2010.
5. Ross JA and Auger MJ: The biology of macrophages. In: The Macrophage. 2nd edition. Burke B and Lewis CE (eds). Oxford University Press, Oxford, 2002.
6. Gordon S and Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964, 2005.
7. Auffray C, Sieweke MH and Geissmann F: Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27: 669-692, 2009.
8. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M and Ley K: Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661, 2010.
9. Geissmann F, Auffray C, Palframan R, et al: Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol 86: 398-408, 2008.
10. Strauss-Ayali D, Conrad SM and Mosser DM: Monocyte sub-populations and their differentiation patterns during infection. J Leukoc Biol 82: 244-252, 2007.
11. Yona S and Jung S: Monocytes: subsets, origins, fates and functions. Curr Opin Hematol 17: 53-59, 2010.
12. Geissmann F, Jung S and Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82, 2003.
13. Torroella-Kouri M, Ma X, Perry G, et al: Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res 65: 10578-10584, 2005.
14. Torroella-Kouri M, Silvera R, Rodriguez D, et al: Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res 69: 4800-4809, 2009.
15. + T cells. J Clin Invest 116: 2777-2790, 2006.
16. Youn JI, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802, 2008.
17. Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506, 2009.
18. Medina D and De Ome KB: Response of hyperplastic alveolar nodule outgrowth-line D1 to mammary tumor virus, nodule-inducing virus, and prolonged hormonal stimulation acting singly and in combination. J Natl Cancer Inst 42: 303-310, 1969.
19. Torroella-Kouri M and Lopez DM: Mammary tumor derived TGFb-1 impairs crucial innate immune response in tumor hosts. J Immunol Immunopathol 5: 31-38, 2003.
20. Torroella-Kouri M, Keith JC, Ivanova M and Lopez DM: IL-11- induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice. Int J Oncol 22: 439-448, 2003.
21. Stuehr DJ and Nathan CF: Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169: 1543-1555, 1989.
22. Calderon CL, Torroella-Kouri M, Dinapoli MR and Lopez DM: Involvement of protein kinase C and not of NF kappa B in the modulation of macrophage nitric oxide synthase by tumor-derived phosphatidyl serine. Int J Oncol 32: 713-721, 2008. (Pubitemid 351336880)
23. De Palma M, Venneri MA, Galli R, et al: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8: 211-226, 2005.
24. Lewis CE, De Palma M and Naldini L: Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angio-poietin- 2. Cancer Res 67: 8429-8432, 2007. (Pubitemid 47437413)
25. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
26. Dai XM, Ryan GR, Hapel AJ, et al: Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99: 111-120, 2002.
27. Hickstein DD, Baker DM, Gollahon KA and Back AL: Identification of the promoter of the myelomonocytic leukocyte integrin CD11b. Proc Natl Acad Sci USA 89: 2105-2109, 1992.
28. Sasmono RT, Oceandy D, Pollard JW, et al: A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 101: 1155-1163, 2003.
29. Sweet MJ and Hume DA: CSF-1 as a regulator of macrophage activation and immune responses. Arch Immunol Ther Exp (Warsz) 51: 169-177, 2003.
30. Auffray C, Fogg D, Garfa M, et al: Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317: 666-670, 2007.
31. Sunderkotter C, Nikolic T, Dillon MJ, et al: Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 172: 4410-4417, 2004. (Pubitemid 38375256)
32. Swirski FK, Libby P, Aikawa E, et al: Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117: 195-205, 2007.
33. Varol C, Yona S and Jung S: Origins and tissue-context-dependent fates of blood monocytes. Immunol Cell Biol 87: 30-38, 2009.
34. Almand B, Clark JI, Nikitina E, et al: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678-689, 2001.
35. Serafini P, Borrello I and Bronte V: Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65, 2006.
36. Imhof BA and Aurrand-Lions M: Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 4: 432-444, 2004.
37. Venneri MA, De Palma M, Ponzoni M, et al: Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109: 5276-5285, 2007.
38. Loveland BE and Cebon J: Cancer exploiting complement: a clue or an exception? Nat Immunol 9: 1205-1206, 2008.
39. Markiewski MM, De Angelis RA, Benencia F, et al: Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225-1235, 2008.
40. Markiewski MM and Lambris JD: Unwelcome complement. Cancer Res 69: 6367-6370, 2009.
41. Markiewski MM and Lambris JD: Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30: 286-292, 2009.
42. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P and Bronte V: Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 267: 216-225, 2008.
43. Melgarejo E, Medina MA, Sanchez-Jimenez F and Urdiales JL: Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 41: 998-1001, 2009.
44. Tacke F, Alvarez D, Kaplan TJ, et al: Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117: 185-194, 2007.
45. Tsou CL, Peters W, Si Y, et al: Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 117: 902-909, 2007. (Pubitemid 46556746)
46. Schioppa T, Uranchimeg B, Saccani A, et al: Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391-1402, 2003.
47. Mantovani A, Allavena P and Sica A: Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 40: 1660-1667, 2004.
48. Jackson RS II, Cho YJ, Stein S and Liang P: CYFIP2, a direct p53 target, is leptomycin-B sensitive. Cell Cycle 6: 95-103, 2007.
49. Li L, Huang L, Sung SS, et al: The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 74: 1526-1537, 2008.
50. Serbina NV and Pamer EG: Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7: 311-317, 2006.
51. Bronte V and Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654, 2005.